FDA Grants Orphan Drug Designation to Tigilanol Tiglate in Soft Tissue Sarcoma
The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma.
Stay updated with breaking news from Soft Tissue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma.
Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.
A microscope scientist working for California State University has been fired following the discovery that a Triceratops horn still contained soft tissue
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer patients expressing PD-L1...
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The